Why the study?
Does transcatheter edge-to-edge repair of the mitral valve reduce hospitalization for heart failure and all-cause mortality in patients with heart failure and symptomatic moderate-to-severe or severe secondary mitral regurgitation?
Does transcatheter edge-to-edge repair of the mitral valve reduce hospitalization for heart failure and all-cause mortality in patients with heart failure and symptomatic moderate-to-severe or severe secondary mitral regurgitation?
Transcatheter edge-to-edge repair provides sustained 5-year benefits in reducing mortality and heart failure hospitalizations for patients with symptomatic secondary mitral regurgitation on guideline-directed medical therapy.
Supports transcatheter edge-to-edge repair in symptomatic secondary mitral regurgitation; extends prior randomized evidence to 5-year outcomes.
Among patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite guideline-directed medical therapy, transcatheter edge-to-edge repair of the mitral valve was safe and led to a lower rate of hospitalization for heart failure and lower all-cause mortality through 5 years of follow-up than medical therapy alone. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079.).
No takes yet. Share an insight, caveat, or question.
Stone et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: